Literature DB >> 2404170

Epidemiology of inflammatory bowel disease.

G Whelan1.   

Abstract

Epidemiologic studies of inflammatory bowel disease indicate that these disorders occur in susceptible individuals, possibly due to genetic abnormalities, resulting in disturbance of bowel wall function. Environmental factor(s) exerting a primary effect at an early age, in most patients, cause the disease to manifest usually in teenagers or young adults. Secondary environmental factors may alter disease expression, severity, or influence relapse. Studies in identical twins provide the best evidence for the role of genetic factors in the cause of Crohn's disease. Changing trends in disease incidence (seen in many countries) provide strong support for environmental factors as playing a major influence in disease expression. We now require further laboratory and epidemiologic studies in family members at risk of disease, in migrants who move from low incidence areas to high incidence areas, and in area where Crohn's disease particularly is starting to appear. The clinician can play an important role by performing careful observations in patients with a view to uncovering new clues to disease etiology.

Entities:  

Keywords:  Americas; Behavior; Biology; Contraception; Contraceptive Methods; Cultural Background; Demographic Factors; Developed Countries; Epidemiologic Methods; Ethnic Groups; Europe; Family Planning; Gastrointestinal Effects; Jews; Literature Review; Measurement; North America; Northern America; Northern Europe; Oral Contraceptives; Physiology; Population; Population Characteristics; Prevalence; Research Methodology; Scandinavia; Smoking; United Kingdom; United States; World

Mesh:

Substances:

Year:  1990        PMID: 2404170     DOI: 10.1016/s0025-7125(16)30581-8

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  17 in total

1.  Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway.

Authors:  B Moum; A Ekbom; M H Vatn; E Aadland; J Sauar; I Lygren; T Schulz; N Stray; O Fausa
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Incidence and prevalence of ulcerative colitis in Punjab, North India.

Authors:  A Sood; V Midha; N Sood; A S Bhatia; G Avasthi
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

3.  Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.

Authors:  J W Singleton; S Hanauer; M Robinson
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

4.  Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.

Authors:  T Andus; R Daig; D Vogl; E Aschenbrenner; G Lock; S Hollerbach; M Köllinger; J Schölmerich; V Gross
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

5.  Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia.

Authors:  Birinder K Mangat; Chad Evaschen; Tim Lee; Eric M Yoshida; Baljinder Salh
Journal:  Can J Gastroenterol       Date:  2011-02       Impact factor: 3.522

Review 6.  Breastfeeding and genetic factors in the etiology of inflammatory bowel disease in children.

Authors:  Theresa A Mikhailov; Sylvia E Furner
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

7.  Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience.

Authors:  Bong Jin Kim; Seung Min Song; Kyung Mo Kim; Yeoun Joo Lee; Kang Won Rhee; Joo Young Jang; Seong Jong Park; Chong Hyun Yoon
Journal:  Dig Dis Sci       Date:  2009-09-10       Impact factor: 3.199

8.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

9.  Inflammatory bowel disease in the Bedouin Arabs of southern Israel: rarity of diagnosis and clinical features.

Authors:  H S Odes; D Fraser; P Krugliak; D Fenyves; G M Fraser; A D Sperber
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

10.  The prevalence of Crohn's disease in Israel: a 20-year survey.

Authors:  Ibrahim Zvidi; Rachel Hazazi; Shlomo Birkenfeld; Yaron Niv
Journal:  Dig Dis Sci       Date:  2008-07-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.